Mastocytosis

Immunology and Allergy Clinics of North America

Volumn 34, Issue 1, 2014, Pages 181-196

  Carter, Melody C ^a   Metcalfe, Dean D ^a   Komarow, Hirsh D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Bone marrow; KIT; Mast cell; Mastocytosis; Skin; Urticaria

Indexed keywords

ADRENALIN; ALPHA2B INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CETIRIZINE; CLADRIBINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; ESTROGEN; FAMOTIDINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYZINE; IMATINIB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MASITINIB; MIDOSTAURIN; OMEPRAZOLE; PROTON PUMP INHIBITOR; PSORALEN; RANITIDINE;

ABDOMINAL PAIN; ANAPHYLAXIS; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; CELL INFILTRATION; CELL PROLIFERATION; CLINICAL FEATURE; DIAGNOSTIC TEST; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FAINTNESS; FEVER; FLUSHING; FRACTURE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; KIT ONCOGENE; MALAISE; MAST CELL; MASTOCYTOSIS; MEDIATOR RELEASE; MUSCULOSKELETAL PAIN; NAUSEA; ONCOGENE; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; PUVA; REVIEW; SKIN; SYSTEMIC MASTOCYTOSIS; URTICARIA PIGMENTOSA;

BONE MARROW; KIT; MAST CELL; MASTOCYTOSIS; SKIN; URTICARIA;

DISEASE PROGRESSION; HUMANS; MASTOCYTOSIS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84888005221     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2013.09.001     Document Type: Review

References (77)

1. Horny H.P., Metcalfe D.D., Bennett J.M., et al. Mastocytosis. World Health Organization (WHO) classification of tumours. Pathology & genetics: tumours of haematopoietic and lymphoid tissues 2008, 54-63. IARC Press, Lyon (France). S. Swerdlow, E. Campo, N.L. Harris (Eds.).
2. Kirshenbaum A.S., Kessler S.W., Goff J.P., et al. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. JImmunol 1991, 146(5):1410-1415.
3. Kirshenbaum A.S., Goff J.P., Semere T., et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 1999, 94(7):2333-2342.
4. Rottem M., Kirshenbaum A.S., Metcalfe D.D. Early development of mast cells. Int Arch Allergy Appl Immunol 1991, 94(1-4):104-109.
5. Rottem M., Okada T., Goff J.P., et al. Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/Fc epsilon RI- cell population. Blood 1994, 84(8):2489-2496.
6. Metcalfe D.D., Mekori J.A., Rottem M. Mast cell ontogeny and apoptosis. Exp Dermatol 1995, 4(4 Pt 2):227-230.
7. Longley B.J., Metcalfe D.D., Tharp M., et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999, 96(4):1609-1614.
8. Horny H.P., Sotlar K., Valent P. Mastocytosis: state of the art. Pathobiology 2007, 74(2):121-132.
9. Wilson T.M., Maric I., Simakova O., et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2011, 96(3):459-463.
10. Sundstrom M., Vliagoftis H., Karlberg P., et al. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology 2003, 108(1):89-97.
11. Valent P. Diagnostic evaluation and classification of mastocytosis. Immunol Allergy Clin North Am 2006, 26(3):515-534.
12. Maric I., Robyn J., Metcalfe D.D., et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. JAllergy Clin Immunol 2007, 120(3):680-687.
13. Akdis C.A., Jutel M., Akdis M. Regulatory effects of histamine and histamine receptor expression in human allergic immune responses. Chem Immunol Allergy 2008, 94:67-82.
14. Castells M., Metcalfe D.D., Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011, 12(4):259-270.
15. Tefferi A., Pardanani A. Systemic mastocytosis: current concepts and treatment advances. Curr Hematol Rep 2004, 3(3):197-202.
16. Escribano L., Akin C., Castells M., et al. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets 2006, 5(1):61-77.
17. Caplan R.M. The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. Arch Dermatol 1963, 87:146-157.
18. Valent P., Akin C., Escribano L., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37(6):435-453.
19. Brockow K., Akin C., Huber M., et al. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. JAm Acad Dermatol 2003, 48(4):508-516.
20. Brockow K., Scott L.M., Worobec A.S., et al. Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease. Arch Dermatol 2002, 138(6):785-790.
21. Wolff K., Komar M., Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001, 25(7):519-528.
22. Cherner J.A., Jensen R.T., Dubois A., et al. Gastrointestinal dysfunction in systemic mastocytosis. A prospective study. Gastroenterology 1988, 95(3):657-667.
23. Sokol H., Georgin-Lavialle S., Canioni D., et al. Gastrointestinal manifestations inmastocytosis: a study of 83 patients. JAllergy Clin Immunol 2013, 132(4). 866-873.e3.
24. Horan R.F., Austen K.F. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. JInvest Dermatol 1991, 96(3):5S-13S. [discussion: 13S-4S].
25. Jensen R.T. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000, 14(3):579-623.
26. Gupta R., Bain B.J., Knight C.L. Cytogenetic and molecular genetic abnormalities in systemic mastocytosis. Acta Haematol 2002, 107(2):123-128.
27. Ammann R.W., Vetter D., Deyhle P., et al. Gastrointestinal involvement in systemic mastocytosis. Gut 1976, 17(2):107-112.
28. Clemett A.R., Fishbone G., Levine R.J., et al. Gastrointestinal lesions in mastocytosis. Am J Roentgenol Radium Ther Nucl Med 1968, 103(2):405-412.
29. Wesley J.R., Vinik A.I., O'Dorisio T.M., et al. Anew syndrome of symptomatic cutaneous mastocytoma producing vasoactive intestinal polypeptide. Gastroenterology 1982, 82(5 Pt 1):963-967.
30. Delsignore J.L., Dvoretsky P.M., Hicks D.G., et al. Mastocytosis presenting as a skeletal disorder. Iowa Orthop J 1996, 16:126-134.
31. Hermine O., Lortholary O., Leventhal P.S., et al. Case-control cohort study of patients' perceptions of disability in mastocytosis. PLoS One 2008, 3(5):e2266.
32. Bonadonna P., Perbellini O., Passalacqua G., et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. JAllergy Clin Immunol 2009, 123(3):680-686.
33. Floman Y., Margulies J.Y., Nyska M., et al. Effect of major axial skeleton trauma on preexisting lumbosacral spondylolisthesis. JSpinal Disord 1991, 4(3):353-358.
34. Lidor C., Frisch B., Gazit D., et al. Osteoporosis as the sole presentation of bone marrow mastocytosis. JBone Miner Res 1990, 5(8):871-876.
35. Rueff F., Przybilla B., Bilo M.B., et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. JAllergy Clin Immunol 2009, 124(5):1047-1054.
36. Travis W.D., Li C.Y. Pathology of the lymph node and spleen in systemic mast cell disease. Mod Pathol 1988, 1(1):4-14.
37. Mican J.M., Di Bisceglie A.M., Fong T.L., et al. Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology 1995, 22(4 Pt 1):1163-1170.
38. Garriga M.M., Friedman M.M., Metcalfe D.D. Asurvey of the number and distribution of mast cells in the skin of patients with mast cell disorders. JAllergy Clin Immunol 1988, 82(3 Pt 1):425-432.
39. Nishioka K., Kobayashi Y., Katayama I., et al. Mast cell numbers in diffuse scleroderma. Arch Dermatol 1987, 123(2):205-208.
40. Elias J., Boss E., Kaplan A.P. Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells. JAllergy Clin Immunol 1986, 78(5 Pt 1):914-918.
41. Mitchell E.B., Crow J., Williams G., et al. Increase in skin mast cells following chronic house dust mite exposure. Br J Dermatol 1986, 114(1):65-73.
42. Amon U., Hartmann K., Horny H.P., et al. Mastocytosis-an update. JDtsch Dermatol Ges 2010, 8(9):695-711. [quiz: 712].
43. Florian S., Krauth M.T., Simonitsch-Klupp I., et al. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 2005, 136(3):273-280.
44. Brockow K., Jofer C., Behrendt H., et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008, 63(2):226-232.
45. Morgado J.M., Sanchez-Munoz L., Teodosio C.G., et al. Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion. Mod Pathol 2012, 25(4):516-521.
46. Hahn H.P., Hornick J.L. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis. Am J Surg Pathol 2007, 31(11):1669-1676.
47. Schwartz L.B., Sakai K., Bradford T.R., et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. JClin Invest 1995, 96(6):2702-2710.
48. Worobec A.S. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000, 14(3):659-687. vii.
49. Horan R.F., Sheffer A.L., Austen K.F. Cromolyn sodium in the management of systemic mastocytosis. JAllergy Clin Immunol 1990, 85(5):852-855.
50. Turk J., Oates J.A., Roberts L.J. Intervention with epinephrine in hypotension associated with mastocytosis. JAllergy Clin Immunol 1983, 71(2):189-192.
51. Godt O., Proksch E., Streit V., et al. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 1997, 195(1):35-39.
52. Czarnetzki B.M., Rosenbach T., Kolde G., et al. Phototherapy of urticaria pigmentosa: clinical response and changes of cutaneous reactivity, histamine and chemotactic leukotrienes. Arch Dermatol Res 1985, 277(2):105-113.
53. Guzzo C., Lavker R., Roberts L.J., et al. Urticaria pigmentosa. Systemic evaluation and successful treatment with topical steroids. Arch Dermatol 1991, 127(2):191-196.
54. Barton J., Lavker R.M., Schechter N.M., et al. Treatment of urticaria pigmentosa with corticosteroids. Arch Dermatol 1985, 121(12):1516-1523.
55. Reisberg I.R., Oyakawa S. Mastocytosis with malabsorption, myelofibrosis, and massive ascites. Am J Gastroenterol 1987, 82(1):54-60.
56. Chen C.C., Andrich M.P., Mican J.M., et al. Aretrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis. JNucl Med 1994, 35(9):1471-1475.
57. Laroche M., Livideanu C., Paul C., et al. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 2011, 124(8):776-778.
58. Pardanani A. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013, 88(7):612-624.
59. Kluin-Nelemans H.C., Jansen J.H., Breukelman H., et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. NEngl J Med 1992, 326(9):619-623.
60. Butterfield J.H. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 1998, 138(3):489-495.
61. Kluin-Nelemans H.C., Oldhoff J.M., Van Doormaal J.J., et al. Cladribine therapy for systemic mastocytosis. Blood 2003, 102(13):4270-4276.
62. Lim K.H., Pardanani A., Butterfield J.H., et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009, 84(12):790-794.
63. Vega-Ruiz A., Cortes J.E., Sever M., et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009, 33(11):1481-1484.
64. Shah N.P., Lee F.Y., Luo R., et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006, 108(1):286-291.
65. Pardanani A., Ketterling R.P., Brockman S.R., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003, 102(9):3093-3096.
66. Gotlib J., Berube C., Growney J.D., et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005, 106(8):2865-2870.
67. Paul C., Sans B., Suarez F., et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 2010, 85(12):921-925.
68. Aichberger K.J., Sperr W.R., Gleixner K.V., et al. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest 2008, 38(11):869-873.
69. Nakamura R., Chakrabarti S., Akin C., et al. Apilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006, 37(4):353-358.
70. Friedman B., Darling G., Norton J., et al. Splenectomy in the management of systemic mast cell disease. Surgery 1990, 107(1):94-100.
71. Kiszewski A.E., Duran-Mckinster C., Orozco-Covarrubias L., et al. Cutaneous mastocytosis in children: a clinical analysis of 71 cases. JEur Acad Dermatol Venereol 2004, 18(3):285-290.
72. Lanternier F., Cohen-Akenine A., Palmerini F., et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS One 2008, 3(4):e1906.
73. Ben-Amitai D., Metzker A., Cohen H.A. Pediatric cutaneous mastocytosis: a review of 180 patients. Isr Med Assoc J 2005, 7(5):320-322.
74. Gadage V.S., Kadam Amare P.S., Galani K.S., et al. Systemic mastocytosis with associated acute myeloid leukemia with t (8; 21) (q22; q22). Indian J Pathol Microbiol 2012, 55(3):409-412.
75. Intzes S., Wiersma S., Meyerson H.J. Myelomastocytic leukemia with t(8;21) in a 3-year-old child. JPediatr Hematol Oncol 2011, 33(8):e372-e375.
76. Lee J.W., Yang W.S., Chung S.Y., et al. Aggressive systemic mastocytosis after germ cell tumor of the ovary: C-KIT mutation documentation in both disease states. JPediatr Hematol Oncol 2007, 29(6):412-415.
77. Mahadeo K.M., Wolgast L., McMahon C., et al. Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia. Pediatr Blood Cancer 2011, 57(4):684-687.